BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share

Reuters

Nov 21

BRIEF-Inhibikase <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Prices Public Offering Of 46 Million Shares At $1.45 Per Share

Nov 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O:

INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
INHIBIKASE THERAPEUTICS INC - PRICES PUBLIC OFFERING OF 46 MILLION SHARES AT $1.45 PER SHARE

Source text: ID:nGNX6cQQC1

Further company coverage: IKT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2585919838"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585919838\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585919838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585919838","market":"us","top_or_hot":-1,"title":"BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Inhibikase <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Prices Public Offering Of 46 Million Shares At $1.45 Per Share</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Inhibikase Therapeutics Inc <span>IKT.O</span>:</p><ul><li><p>INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION PUBLIC OFFERING  OF COMMON STOCK AND PRE-FUNDED WARRANTS</p></li><li><p>INHIBIKASE THERAPEUTICS INC - PRICES PUBLIC OFFERING OF 46 MILLION SHARES AT $1.45 PER SHARE</p></li></ul><p>Source text: <span>ID:nGNX6cQQC1</span></p><p>Further company coverage: <span>IKT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 10:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Inhibikase <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Prices Public Offering Of 46 Million Shares At $1.45 Per Share</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Inhibikase Therapeutics Inc <span>IKT.O</span>:</p><ul><li><p>INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION PUBLIC OFFERING  OF COMMON STOCK AND PRE-FUNDED WARRANTS</p></li><li><p>INHIBIKASE THERAPEUTICS INC - PRICES PUBLIC OFFERING OF 46 MILLION SHARES AT $1.45 PER SHARE</p></li></ul><p>Source text: <span>ID:nGNX6cQQC1</span></p><p>Further company coverage: <span>IKT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IKT","symbol_name":"Inhibikase Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUARRFB5:1","article_id":"2585919838","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585919838","pubTimestamp":1763693837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per ShareNov 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O:INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IKT":"Inhibikase Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Inhibikase Therapeutics公开发行4600万股股票的定价为每股1.45美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IKT":0.9},"content_text":"BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per ShareNov 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O:INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION PUBLIC OFFERING  OF COMMON STOCK AND PRE-FUNDED WARRANTSINHIBIKASE THERAPEUTICS INC - PRICES PUBLIC OFFERING OF 46 MILLION SHARES AT $1.45 PER SHARESource text: ID:nGNX6cQQC1Further company coverage: IKT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}